Found: 93
Select item for more details and to access through your institution.
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
- Published in:
- Oncologist, 2024, v. 29, n. 4, p. e514, doi. 10.1093/oncolo/oyad338
- By:
- Publication type:
- Article
Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 3, p. 400, doi. 10.1002/cncr.35063
- By:
- Publication type:
- Article
Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 3, p. 1, doi. 10.1002/cam4.6877
- By:
- Publication type:
- Article
Therapeutic Role of Synthetic Lethality in ARID1A-Deficient Malignancies.
- Published in:
- Journal of Immunotherapy & Precision Oncology, 2024, v. 7, n. 1, p. 41, doi. 10.36401/JIPO-22-37
- By:
- Publication type:
- Article
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
- Published in:
- Oncologist, 2023, v. 28, n. 12, p. 1100, doi. 10.1093/oncolo/oyad158
- By:
- Publication type:
- Article
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 107, doi. 10.1007/s00280-023-04545-4
- By:
- Publication type:
- Article
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 4, p. 517, doi. 10.1007/s11523-023-00965-7
- By:
- Publication type:
- Article
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00369-w
- By:
- Publication type:
- Article
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-022-00341-0
- By:
- Publication type:
- Article
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology.
- Published in:
- NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-022-00317-0
- By:
- Publication type:
- Article
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-16588-3
- By:
- Publication type:
- Article
Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials.
- Published in:
- Cancers, 2022, v. 14, n. 15, p. 3695, doi. 10.3390/cancers14153695
- By:
- Publication type:
- Article
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-12669-5
- By:
- Publication type:
- Article
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 2, p. 290, doi. 10.1007/s10637-021-01188-1
- By:
- Publication type:
- Article
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 99, doi. 10.1007/s10637-021-01153-y
- By:
- Publication type:
- Article
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 124, doi. 10.1007/s10637-021-01184-5
- By:
- Publication type:
- Article
Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 2, p. 340, doi. 10.1002/cam4.4446
- By:
- Publication type:
- Article
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors.
- Published in:
- 2021
- By:
- Publication type:
- Letter
A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-01707-3
- By:
- Publication type:
- Article
Patient‐Reported Out‐of‐Pocket Costs and Financial Toxicity During Early‐Phase Oncology Clinical Trials.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. 588, doi. 10.1002/onco.13767
- By:
- Publication type:
- Article
Overview of Ocular Side Effects of Selinexor.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. 619, doi. 10.1002/onco.13756
- By:
- Publication type:
- Article
A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies.
- Published in:
- OncoTargets & Therapy, 2021, v. 14, p. 3037, doi. 10.2147/OTT.S291801
- By:
- Publication type:
- Article
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study.
- Published in:
- NPJ Precision Oncology, 2021, v. 5, n. 1, p. 1, doi. 10.1038/s41698-021-00159-2
- By:
- Publication type:
- Article
Associations between the gut microbiome and fatigue in cancer patients.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-84783-9
- By:
- Publication type:
- Article
Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings.
- Published in:
- Oncologist, 2020, v. 25, n. 11, p. e1628, doi. 10.1634/theoncologist.2020-0520
- By:
- Publication type:
- Article
Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas.
- Published in:
- Cancers, 2020, v. 12, n. 8, p. 2307, doi. 10.3390/cancers12082307
- By:
- Publication type:
- Article
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
- Published in:
- Experimental Hematology & Oncology, 2020, v. 9, n. 1, p. 1, doi. 10.1186/s40164-020-00159-1
- By:
- Publication type:
- Article
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.
- Published in:
- Journal of Hematology & Oncology, 2019, v. 12, n. 1, p. 1, doi. 10.1186/s13045-019-0835-1
- By:
- Publication type:
- Article
Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1204, doi. 10.1002/jcph.1416
- By:
- Publication type:
- Article
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 601, doi. 10.1007/s10637-017-0524-2
- By:
- Publication type:
- Article
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 638, doi. 10.1007/s10637-017-0534-0
- By:
- Publication type:
- Article
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 3, p. 416, doi. 10.1007/s10637-017-0513-5
- By:
- Publication type:
- Article
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials.
- Published in:
- British Journal of Cancer, 2018, v. 118, n. 6, p. 763, doi. 10.1038/bjc.2017.480
- By:
- Publication type:
- Article
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 616, doi. 10.1007/s10637-017-0442-3
- By:
- Publication type:
- Article
Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 1, p. 59, doi. 10.1007/s10637-016-0395-y
- By:
- Publication type:
- Article
Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.
- Published in:
- International Journal of Cancer, 2017, v. 140, n. 1, p. 208, doi. 10.1002/ijc.30417
- By:
- Publication type:
- Article
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit.
- Published in:
- Oncology, 2017, v. 92, n. 1, p. 14, doi. 10.1159/000449505
- By:
- Publication type:
- Article
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.
- Published in:
- Cancer Medicine, 2016, v. 5, n. 12, p. 3437, doi. 10.1002/cam4.956
- By:
- Publication type:
- Article
Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.
- Published in:
- Scientific Reports, 2016, p. 35448, doi. 10.1038/srep35448
- By:
- Publication type:
- Article
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
- Published in:
- British Journal of Clinical Pharmacology, 2016, v. 82, n. 3, p. 728, doi. 10.1111/bcp.12991
- By:
- Publication type:
- Article
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
- Published in:
- 2016
- By:
- Publication type:
- journal article